News Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
5,131 ^JPY	+0.51%		-4.95%	-3.95%

Apr. 10	Japan's Nikkei slips on caution ahead of US inflation data	RE
Mar. 29	Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	Apr. 15	AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	Apr. 10	AQ
Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	Mar. 28	AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	Mar. 28	PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	Mar. 27	AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	Mar. 27	AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	Mar. 27	AQ
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Chugai Pharmaceutical : Finance Report (Jan-Dec 2023) (Posted on March 28)	Mar. 24	PU
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors	Mar. 01	AQ
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Chugai Pharmaceutical - Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Phase I study for Relapsed and Refractory Follicular Lymphoma	Feb. 09	AQ
Chugai Pharmaceutical - Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria	Feb. 09	AQ
Chugai Awarded Highest A-Rating by CDP in Climate Change and Water Security	Feb. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Summary

Filters